1. Home
  2. KRNY vs STTK Comparison

KRNY vs STTK Comparison

Compare KRNY & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$8.06

Market Cap

511.9M

Sector

Finance

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$7.28

Market Cap

569.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
STTK
Founded
1884
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
511.9M
569.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
KRNY
STTK
Price
$8.06
$7.28
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$8.50
$10.00
AVG Volume (30 Days)
257.6K
421.2K
Earning Date
04-23-2026
05-01-2026
Dividend Yield
5.33%
N/A
EPS Growth
130.22
53.02
EPS
0.30
N/A
Revenue
$2,580,000.00
$1,000,000.00
Revenue This Year
$3.89
N/A
Revenue Next Year
$17.52
N/A
P/E Ratio
$27.50
N/A
Revenue Growth
36.00
N/A
52 Week Low
$5.76
$0.71
52 Week High
$8.50
$8.33

Technical Indicators

Market Signals
Indicator
KRNY
STTK
Relative Strength Index (RSI) 55.49 55.06
Support Level $7.77 $1.85
Resistance Level $8.27 $7.68
Average True Range (ATR) 0.22 0.49
MACD 0.01 -0.07
Stochastic Oscillator 74.52 31.21

Price Performance

Historical Comparison
KRNY
STTK

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: